drug
(ethinylestradiol + segesterone acetate) ER
Marketedupdated 3mo agoby Mayne Pharma USA Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 1, 2039
~12.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Jun 21, 2039formulationUS 10918649
- Jun 21, 2039formulationUS 10925882
- Jun 21, 2039formulationUS 10940157
- Jun 21, 2039formulationUS 11529308
- Jun 21, 2039method-of-use (U-3785)US 11850251
- Jun 21, 2039formulationUS 12303518
- Feb 1, 2039method-of-use (U-2786)US 10632066
- Feb 1, 2039method-of-use (U-2787)US 10765628
- Feb 1, 2039method-of-use (U-2786)US 10780047
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that